Abstract: An oral dosage form of a compound selected from boronic acids which have a neutral thrombin (P1) domain linked to a hydrophobic moiety capable of binding to the thrombin (S2) and (S3) subsites, and salts, prodrugs and prodrug salts of such acids, the dosage form comprising a solid phase formulation comprising the compound and being adapted for reconstitution of the formulation to form a liquid preparation.
Type:
Application
Filed:
March 9, 2005
Publication date:
July 10, 2008
Applicant:
Trigen Holdings AG Clareville House
Inventors:
Guy Michael Patrick, Sophie Marie Combe-Marzelle, Anthony James Kennedy, Roger Withington, Oliver Vimpany Arnold Boucher